Operaciones Fortress Biotech - FBIO CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | - | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Fortress Biotech Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | N/A |
| Abrir* | N/A |
| Cambio de 1 año* | N/A |
| Rango del día* | N/A |
| Rango de 52 semanas | 0.48-1.33 |
| Volumen medio (10 días) | 1.42M |
| Volumen medio (3 meses) | 12.40M |
| Capitalización de mercado | 73.21M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 134.33M |
| Ingresos | 64.25M |
| EPS | -1.00 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 2.00 |
| Próxima fecha de resultados | Aug 9, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|
Fortress Biotech Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Wednesday, June 14, 2023 | ||
| Hora (UTC) (UTC) 12:00 | País US
| Evento Fortress Biotech Inc Fortress Biotech IncForecast -Previous - |
| Wednesday, June 21, 2023 | ||
| Hora (UTC) (UTC) 14:00 | País US
| Evento Fortress Biotech Inc Annual Shareholders Meeting Fortress Biotech Inc Annual Shareholders MeetingForecast -Previous - |
| Hora (UTC) (UTC) 14:00 | País US
| Evento Fortress Biotech Inc Annual Shareholders Meeting Fortress Biotech Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 9, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q2 2023 Fortress Biotech Inc Earnings Release Q2 2023 Fortress Biotech Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Hora (UTC) (UTC) 21:01 | País US
| Evento Q3 2023 Fortress Biotech Inc Earnings Release Q3 2023 Fortress Biotech Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 75.743 | 68.791 | 45.599 | 36.629 | 26.882 |
| Ingresos | 75.743 | 68.791 | 45.599 | 36.629 | 26.882 |
| Coste de los ingresos, total | 30.775 | 32.084 | 14.594 | 10.532 | 6.125 |
| Beneficio bruto | 44.968 | 36.707 | 31.005 | 26.097 | 20.757 |
| Gastos totales de explotación | 279.307 | 257.332 | 139.869 | 128.972 | 146.442 |
| Gastos de venta/general/administración Gastos, total | 113.656 | 86.843 | 61.166 | 55.59 | 53.371 |
| Investigación y desarrollo | 134.876 | 128.865 | 64.109 | 81.326 | 87.383 |
| Gastos (ingresos) extraordinarios | 0 | 9.54 | 0 | -18.476 | -0.437 |
| Other Operating Expenses, Total | |||||
| Ingresos de explotación | -203.564 | -188.541 | -94.27 | -92.343 | -119.56 |
| Ingresos por intereses (gastos), netos No operativos | -11.204 | 24.188 | -8.579 | -9.317 | -11.308 |
| Ingresos netos antes de impuestos | -213.464 | -164.353 | -102.849 | -101.66 | -130.8 |
| Ingresos netos después de impuestos | -213.913 | -164.826 | -102.985 | -101.66 | -130.8 |
| Intereses menores | 127.338 | 100.123 | 56.459 | 61.7 | 57.789 |
| Beneficio neto antes de partidas extra. Elementos | -86.575 | -64.703 | -46.526 | -39.96 | -73.011 |
| Ingresos netos | -86.575 | -64.703 | -46.526 | -39.96 | -84.147 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -86.575 | -64.703 | -46.526 | -39.96 | -73.011 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -86.575 | -64.703 | -46.526 | -39.96 | -84.147 |
| Beneficio neto diluido | -86.575 | -64.703 | -46.526 | -39.96 | -84.147 |
| Promedio ponderado de acciones diluidas | 88.8745 | 81.7002 | 72.0052 | 54.7118 | 43.462 |
| BPA diluido sin partidas extraordinarias | -0.97413 | -0.79196 | -0.64615 | -0.73037 | -1.67988 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA normalizado diluido | -0.97413 | -0.71606 | -0.64615 | -1.06807 | -1.68994 |
| Otros, netos | 1.304 | 0 | 0.068 | ||
| Total de partidas extraordinarias | 0 | -11.136 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 12.429 | 16.404 | 16.528 | 18.886 | 23.925 |
| Ingresos | 12.429 | 16.404 | 16.528 | 18.886 | 23.925 |
| Coste de los ingresos, total | 6.449 | 7.718 | 7.221 | 7.633 | 8.203 |
| Beneficio bruto | 5.98 | 8.686 | 9.307 | 11.253 | 15.722 |
| Gastos totales de explotación | 71.296 | 71.038 | 67.262 | 69.812 | 71.195 |
| Gastos de venta/general/administración Gastos, total | 25.341 | 28.199 | 30.139 | 29.048 | 26.27 |
| Investigación y desarrollo | 39.506 | 35.121 | 29.902 | 33.131 | 36.722 |
| Ingresos de explotación | -58.867 | -54.634 | -50.734 | -50.926 | -47.27 |
| Ingresos por intereses (gastos), netos No operativos | 3.371 | -2.997 | -2.995 | -3.004 | -2.208 |
| Ingresos netos antes de impuestos | -55.145 | -56.996 | -53.06 | -53.93 | -49.478 |
| Ingresos netos después de impuestos | -55.145 | -57.445 | -53.06 | -53.93 | -49.478 |
| Intereses menores | 33.608 | 30.497 | 30.549 | 32.574 | 33.718 |
| Beneficio neto antes de partidas extra. Elementos | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Ingresos netos | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Beneficio neto diluido | -21.537 | -26.948 | -22.511 | -21.356 | -15.76 |
| Promedio ponderado de acciones diluidas | 101.886 | 90.6222 | 89.4249 | 88.7435 | 86.2551 |
| BPA diluido sin partidas extraordinarias | -0.21138 | -0.29737 | -0.25173 | -0.24065 | -0.18271 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.21138 | -0.29737 | -0.25173 | -0.24065 | -0.18271 |
| Gastos (ingresos) extraordinarios | 0 | 0 | |||
| Otros, netos | 0.351 | 0.635 | 0.669 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 230.432 | 346.462 | 266.15 | 156.252 | 111.207 |
| Efectivo e inversiones a corto plazo | 178.266 | 305.744 | 233.351 | 136.858 | 83.112 |
| Efectivo y Equivalentes | 178.266 | 305.744 | 233.351 | 136.858 | 65.508 |
| Inversiones a corto plazo | 0 | 17.604 | |||
| Total deudores, neto | 28.346 | 23.79 | 24.672 | 14.404 | 7.593 |
| Accounts Receivable - Trade, Net | 28.208 | 23.112 | 23.928 | 13.539 | 5.498 |
| Total Inventory | 14.159 | 9.862 | 1.404 | 0.857 | 0.678 |
| Prepaid Expenses | 9.661 | 7.066 | 6.723 | 4.133 | 6.735 |
| Other Current Assets, Total | 0 | 13.089 | |||
| Total Assets | 294.301 | 396.503 | 333.413 | 226.422 | 140.993 |
| Property/Plant/Equipment, Total - Net | 33.011 | 34.071 | 32.41 | 33.913 | 12.019 |
| Property/Plant/Equipment, Total - Gross | 45.457 | 43.465 | 39.176 | 38.399 | 14.583 |
| Accumulated Depreciation, Total | -12.446 | -9.394 | -6.766 | -4.486 | -2.564 |
| Goodwill, Net | |||||
| Intangibles, Net | 27.197 | 12.552 | 14.629 | 7.377 | 1.417 |
| Long Term Investments | 0 | 17.566 | 11.148 | 0 | |
| Other Long Term Assets, Total | 3.661 | 3.418 | 2.658 | 17.732 | 16.35 |
| Total Current Liabilities | 127.715 | 101.042 | 51.76 | 45.616 | 55.614 |
| Payable/Accrued | 19.857 | 19.986 | 17.054 | 22.906 | 34.216 |
| Accrued Expenses | 22.792 | 25.349 | 18.636 | 15.463 | 1.329 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 7.235 | 4.51 | 4.522 | 7.22 | 19.078 |
| Other Current Liabilities, Total | 20.587 | 3.768 | 0.136 | 0.027 | 0.991 |
| Total Liabilities | 252.58 | 287.829 | 233.075 | 200.207 | 139.141 |
| Total Long Term Debt | 93.142 | 46.564 | 59.814 | 82.426 | 60.425 |
| Long Term Debt | 93.142 | 46.564 | 59.814 | 82.426 | 60.425 |
| Minority Interest | 8.304 | 117.203 | 96.661 | 46.317 | 17.891 |
| Other Liabilities, Total | 23.419 | 23.02 | 24.84 | 25.848 | 5.211 |
| Total Equity | 41.721 | 108.674 | 100.338 | 26.215 | 1.852 |
| Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.001 | 0.001 |
| Common Stock | 0.11 | 0.101 | 0.095 | 0.574 | 0.717 |
| Additional Paid-In Capital | 675.841 | 656.033 | 583 | 461.874 | 397.408 |
| Retained Earnings (Accumulated Deficit) | -634.233 | -547.463 | -482.76 | -436.234 | -396.274 |
| Total Liabilities & Shareholders’ Equity | 294.301 | 396.503 | 333.413 | 226.422 | 140.993 |
| Total Common Shares Outstanding | 110.494 | 101.436 | 94.8775 | 74.0274 | 57.8455 |
| Total Preferred Shares Outstanding | 3.42714 | 3.42714 | 3.42714 | 1.34117 | |
| Accounts Payable | 57.244 | 47.429 | 11.412 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 202.381 | 230.432 | 257.994 | 298.991 | 341.186 |
| Efectivo e inversiones a corto plazo | 152.483 | 178.266 | 208.351 | 248.771 | 287.511 |
| Efectivo y Equivalentes | 152.483 | 178.266 | 208.351 | 248.771 | 287.511 |
| Total deudores, neto | 28.252 | 28.346 | 28.686 | 29.047 | 31.814 |
| Accounts Receivable - Trade, Net | 27.616 | 28.208 | 28.533 | 28.671 | 31.183 |
| Total Inventory | 13.278 | 14.159 | 15.23 | 16.053 | 16.137 |
| Prepaid Expenses | 8.368 | 9.661 | 5.727 | 5.12 | 5.724 |
| Total Assets | 263.551 | 294.301 | 323.561 | 363.955 | 407.93 |
| Property/Plant/Equipment, Total - Net | 31.661 | 33.011 | 33.529 | 32.137 | 32.995 |
| Property/Plant/Equipment, Total - Gross | 44.951 | 45.457 | 45.152 | 43.026 | 43.128 |
| Accumulated Depreciation, Total | -13.29 | -12.446 | -11.623 | -10.889 | -10.133 |
| Intangibles, Net | 26.128 | 27.197 | 28.424 | 29.44 | 30.457 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 3.381 | 3.661 | 3.614 | 3.387 | 3.292 |
| Total Current Liabilities | 129.473 | 127.715 | 106.303 | 104.921 | 103.14 |
| Payable/Accrued | 20.959 | 19.857 | 18.35 | 20.655 | 22.269 |
| Accrued Expenses | 21.107 | 22.792 | 21.973 | 21.038 | 26.596 |
| Notes Payable/Short Term Debt | 2.318 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.288 | 7.235 | 9.122 | 7.487 | 7.363 |
| Other Current Liabilities, Total | 16.933 | 20.587 | 1.093 | 1.802 | 2.38 |
| Total Liabilities | 225.755 | 252.58 | 261.89 | 286.732 | 310.071 |
| Total Long Term Debt | 91.446 | 93.142 | 92.539 | 89.419 | 88.772 |
| Long Term Debt | 91.446 | 93.142 | 92.539 | 89.419 | 88.772 |
| Minority Interest | -17.99 | 8.304 | 39.681 | 70.479 | 95.719 |
| Other Liabilities, Total | 22.826 | 23.419 | 23.367 | 21.913 | 22.44 |
| Total Equity | 37.796 | 41.721 | 61.671 | 77.223 | 97.859 |
| Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Common Stock | 0.13 | 0.11 | 0.108 | 0.108 | 0.106 |
| Additional Paid-In Capital | 693.433 | 675.841 | 668.65 | 661.691 | 660.973 |
| Retained Earnings (Accumulated Deficit) | -655.77 | -634.233 | -607.09 | -584.579 | -563.223 |
| Total Liabilities & Shareholders’ Equity | 263.551 | 294.301 | 323.561 | 363.955 | 407.93 |
| Total Common Shares Outstanding | 130.417 | 110.494 | 108.259 | 107.718 | 106.322 |
| Total Preferred Shares Outstanding | 3.42714 | 3.42714 | 3.42714 | 3.42714 | 3.42714 |
| Accounts Payable | 65.868 | 57.244 | 55.765 | 53.939 | 44.532 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -213.913 | -164.826 | -102.985 | -101.66 | -141.936 |
| Efectivo de actividades de explotación | -179.401 | -116.54 | -83.682 | -94.961 | -98.848 |
| Efectivo de actividades de explotación | 3.109 | 2.628 | 2.28 | 1.922 | 1.393 |
| Amortization | 4.277 | 2.474 | 1.42 | 1.174 | 0.666 |
| Deferred Taxes | |||||
| Partidas no monetarias | 27.841 | 6.811 | 20.384 | 8.444 | 35.293 |
| Intereses pagados en efectivo | 9.419 | 6.918 | 8.821 | 5.9 | 4.729 |
| Cambios en el capital circulante | -0.715 | 36.373 | -4.781 | -4.841 | 5.736 |
| Efectivo de actividades de inversión | -22.928 | 40.514 | -7.164 | 20.097 | 18.824 |
| Gastos de capital | -2.715 | -4.966 | -3.126 | -4.745 | -8.282 |
| Otras partidas de flujo de caja de inversión, total | -20.213 | 45.48 | -4.038 | 24.842 | 27.106 |
| Efectivo procedente de actividades de financiación | 75.319 | 148.994 | 172.41 | 146.714 | 50.648 |
| Elementos de flujo de caja de financiación | 14.156 | 119.232 | 41.47 | 76.118 | 20.309 |
| Total Cash Dividends Paid | -8.78 | -8.78 | -6.752 | -2.559 | -2.344 |
| Emisión (retiro) de acciones, neto | 25.695 | 44.73 | 167.363 | 58.155 | 15.788 |
| Emisión (amortización) de deuda, neta | 44.248 | -6.188 | -29.671 | 15 | 16.895 |
| Variación neta de la tesorería | -127.01 | 72.968 | 81.564 | 71.85 | -29.376 |
| Cash Taxes Paid | 0.858 | 0.993 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -55.145 | -213.913 | -156.468 | -103.408 | -49.478 |
| Cash From Operating Activities | -43.22 | -179.401 | -131.557 | -88.284 | -46.86 |
| Cash From Operating Activities | 0.844 | 3.109 | 2.286 | 1.495 | 0.739 |
| Amortization | 1.069 | 4.277 | 3.05 | 2.034 | 1.017 |
| Non-Cash Items | 3.866 | 27.841 | 21.303 | 13.056 | 6.519 |
| Cash Interest Paid | 2.885 | 9.419 | 6.595 | 3.987 | 1.556 |
| Changes in Working Capital | 6.146 | -0.715 | -1.728 | -1.461 | -5.657 |
| Cash From Investing Activities | -5 | -22.928 | -22.537 | -21.644 | -21.337 |
| Capital Expenditures | 0 | -2.715 | -2.624 | -1.644 | -1.337 |
| Cash From Financing Activities | 22.187 | 75.319 | 56.701 | 52.955 | 49.964 |
| Financing Cash Flow Items | 9.703 | 14.156 | 13.997 | 12.309 | 5.745 |
| Total Cash Dividends Paid | -2.194 | -8.78 | -6.587 | -4.391 | -2.195 |
| Issuance (Retirement) of Stock, Net | 14.626 | 25.695 | 5.991 | 5.737 | 4.226 |
| Issuance (Retirement) of Debt, Net | 0.052 | 44.248 | 43.3 | 39.3 | 42.188 |
| Net Change in Cash | -26.033 | -127.01 | -97.393 | -56.973 | -18.233 |
| Other Investing Cash Flow Items, Total | -5 | -20.213 | -19.913 | -20 | -20 |
| Cash Taxes Paid | 0.858 | 1.462 | 0.166 | 0.107 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Rosenwald (Lindsay A M.D.) | Individual Investor | 11.4268 | 15349091 | 0 | 2023-03-31 | LOW |
| Weiss (Michael S) | Individual Investor | 10.9823 | 14752034 | 0 | 2023-03-31 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 5.1501 | 6917876 | -1050180 | 2023-03-31 | LOW |
| Dak Capital Inc | Corporation | 4.5062 | 6052975 | 6052975 | 2023-02-10 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8973 | 5235107 | 130700 | 2023-03-31 | LOW |
| Opaleye Management Inc. | Hedge Fund | 3.4049 | 4573600 | 2523600 | 2023-03-31 | LOW |
| Jefferies LLC | Research Firm | 2.1217 | 2850000 | -1450000 | 2023-03-31 | HIGH |
| Lobell (J Jay) | Individual Investor | 1.2175 | 1635401 | 0 | 2023-03-31 | LOW |
| Jin (David) | Individual Investor | 1.113 | 1495007 | 1350000 | 2023-03-31 | HIGH |
| Perkins Capital Management, Inc. | Investment Advisor | 1.0564 | 1419013 | 596500 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.0346 | 1389678 | -3845 | 2023-03-31 | LOW |
| Medical Strategy GmbH | Investment Advisor | 1.0268 | 1379308 | -156278 | 2023-01-31 | LOW |
| Shikiar Asset Management, Inc. | Investment Advisor | 0.8703 | 1169000 | 327500 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.761 | 1022233 | 263672 | 2023-03-31 | MED |
| Rowinsky (Eric K. M.D.) | Individual Investor | 0.7113 | 955466 | 223490 | 2023-03-31 | |
| CI Private Wealth, LLC | Investment Advisor | 0.6812 | 915053 | 122786 | 2023-03-31 | LOW |
| Columbia Pacific Wealth Management | Investment Advisor | 0.5675 | 762267 | -19500 | 2022-09-30 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5198 | 698287 | 20065 | 2023-03-31 | LOW |
| Avgerinos (George C) | Individual Investor | 0.4877 | 655170 | 0 | 2023-03-31 | LOW |
| Foord Asset Management (Pty) Limited | Investment Advisor/Hedge Fund | 0.3226 | 433340 | -355740 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Fortress Biotech Company profile
Sobre Fortress Biotech Inc
Fortress Biotech, Inc. (Fortress) es una empresa biofarmacéutica que adquiere, desarrolla y comercializa productos farmacéuticos y biotecnológicos y candidatos a productos. Fortress tiene siete productos farmacéuticos de prescripción comercializados y más de 25 programas en desarrollo en Fortress, y en sus empresas asociadas. Sus productos candidatos abarcan seis áreas de mercado, incluyendo la oncología, las enfermedades raras y la terapia génica. Los productos comercializados de la empresa son Ximino, Targadox, Exelderm, Ceracade, Luxamend y Accutane. Sus productos candidatos en fase avanzada incluyen Tramadol intravenoso (IV), CUTX-101, MB-107 y MB-207, Cosibelimab, CK-101, CAEL-101, Triplex y CEVA101. Sus productos candidatos también son MB-102 (CD123 CAR T para BPDCN), MB-101 (IL13Ra2 CAR T para Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 y ConVax. La empresa opera en dos segmentos operativos y reportables: Ventas de productos dermatológicos y Desarrollo de productos farmacéuticos y biotecnológicos.
El precio actual de la acción Fortress Biotech en tiempo real es 0 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Golden Entertainment, Spero Therapeutics, Inc., HP, Discover Financial Services, LYFT y Waste Management. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biopharmaceuticals |
1111 Kane Concourse
Suite 301
BAY HARBOR ISLANDS
FLORIDA 33154
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com